Sugi Predict

Sugi Predict / Compounds / SCHEMBL2226336

SCHEMBL2226336

SCHEMBL2226336

N#CCc1nc(-c2ccc(Br)cc2)cs1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.57
▸ SMN1; SMN2 Q16637 7/20 0.57
▸ RAB9A P51151 6/20 0.57
▸ MEN1 O00255 6/20 0.57
▸ KMT2A Q03164 6/20 0.57
▸ ALDH1A1 P00352 5/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ GAA P10253 2/20 0.57
▸ LMNA P02545 5/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.50
▸ HDAC3 O15379 1/20 0.48
▸ HDAC4 P56524 1/20 0.48
▸ HDAC1 Q13547 1/20 0.48
▸ HDAC7 Q8WUI4 1/20 0.48
▸ HDAC2 Q92769 1/20 0.48
▸ HDAC10 Q969S8 1/20 0.48
▸ HDAC11 Q96DB2 1/20 0.48
▸ HDAC8 Q9BY41 1/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.48
▸ HDAC9 Q9UKV0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5093936 0.84 GAA (0.59) MAPTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2226546 0.84 ALDH1A1 (0.56) MAPTSMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL2224879 0.84 ALDH1A1 (0.53) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL5100319 0.84 RAB9A (0.56) MAPTSMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL2226576 0.83 LOXL2 (0.58) MAPTSMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL2223579 0.83 LOXL2 (0.58) MAPTSMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL2225361 0.80 MAPT (0.60) MAPTSMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL2225749 0.80 L3MBTL1 (0.53) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL17887306 0.80 ALDH1A1 (0.41) MAPTSMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL28476993 0.80 SMN1; SMN2 (0.64) MAPTSMN1; SMN2RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3928836-B1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-09-18 — — EP disclosed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 — — US disclosed
EP-3377483-B9 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-08-03 — — EP disclosed
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 — — US disclosed
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2022-02-08 — — US disclosed
EP-3928836-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2021-12-29 — — EP disclosed
CN-108349949-B N-substituted indole derivatives as PGE2 receptor modulators 爱杜西亚药品有限公司 2020-11-17 — — CN disclosed
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2020-09-17 — — US disclosed
EP-3377483-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2018-09-26 — — EP disclosed
CN-108349949-A N- substituted indole derivatives as PGE2 receptor modulators 爱杜西亚药品有限公司 2018-07-31 — — CN disclosed
CN-103221047-A Compounds and methods TEMPERO PHARMACEUTICALS INC 2013-07-24 — — CN disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 — — US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 — — US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 — — US disclosed
WO-2011088181-A9 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-31 — — WO disclosed
WO-2011088181-A9 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-31 — — WO disclosed
EP-2533783-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals, Inc. (US) 2012-12-19 — — EP disclosed
WO-2011088181-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed
US-20060122387-A1 Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells CTI EUROPE S.R.L. 2006-06-08 — — US disclosed
WO-2003105842-A1 DERIVATIVES OF CHROMEN-2-ONE AS INHIBITORS OF VEGF PRODUCTION IN MAMMALIAN CELLS NOVUSPHARMA S.P.A. (IT) 2003-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 MAPT 4570/4885SMN1; SMN2 4553/4885RAB9A 3072/4885
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 MAPT 4570/4885SMN1; SMN2 4553/4885RAB9A 3072/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 MAPT 4570/4885SMN1; SMN2 4553/4885RAB9A 3072/4885
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 MAPT 4570/4885SMN1; SMN2 4553/4885RAB9A 3072/4885
US-20060122387-A1 Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells KDR, FLT1, VEGFA MAPT 4137/4885SMN1; SMN2 4200/4885RAB9A 2757/4885
US-20130059883-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY MAPT 4479/4885SMN1; SMN2 3005/4885RAB9A 1528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.